Compare JPC & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JPC | SRPT |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 2003 | 2000 |
| Metric | JPC | SRPT |
|---|---|---|
| Price | $8.06 | $17.11 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 28 |
| Target Price | N/A | ★ $25.76 |
| AVG Volume (30 Days) | 956.7K | ★ 2.0M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $6.79 | $10.42 |
| 52 Week High | $8.30 | $80.26 |
| Indicator | JPC | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 45.46 |
| Support Level | $7.99 | $17.05 |
| Resistance Level | $8.16 | $19.55 |
| Average True Range (ATR) | 0.06 | 0.83 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 33.87 | 63.11 |
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its primary investment objective is to provide high current income, and its secondary investment objective is total return. The fund invests a majority of its assets in preferred securities and other income-producing securities, including hybrid securities such as contingent capital securities, and the rest of its investments are made in other securities, mainly income-oriented securities such as corporate and taxable municipal debt and common equity.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.